Five Chinese Pharmaceutical Companies Listed in China's Top 100 Strategic Emerging Industry Enterprises

　　【Pharmaceutical Network | Industry Dynamics] On the morning of September 1, at the Top 500 Chinese Enterprises Summit Forum 2019, the “Top 100 Leading Enterprises in China’s Strategic Emerging Industries” list was released. The list showed that Huawei Investment Holding Co., Ltd. ranked first with a total strategic emerging industry revenue of RMB 721.2 billion, followed by China Mobile Communications Group Co., Ltd. and Beijing Jingdong Century Trading Co., Ltd. in second and third places, with total strategic emerging industry revenues of RMB 536.4 billion and RMB 462.0 billion, respectively. In addition, according to the author’s analysis, five enterprises from the pharmaceutical and biomanufacturing sector made it onto the list.
 

Qilu Pharmaceutical: 63rd
 

According to the rankings, Qilu Pharmaceutical ranked 63rd with a total strategic emerging industry revenue of RMB 21.10972 billion.
 

Public information indicates that Qilu Pharmaceutical adheres to an innovation-driven development strategy and extensively expands scientific research and development collaborations both domestically and internationally. 2018 was a year in which multiple business segments of Qilu Pharmaceutical, including human pharmaceutical raw materials and formulations, as well as agricultural and veterinary drugs, exerted concerted efforts. The group’s total export value for the year reached USD 615 million, representing a 36% increase compared to the previous year.
 

CSPC Pharmaceutical Group Limited: 71st
 

CSPC ranked 71st with a total revenue of RMB 18.98235 billion from strategic emerging industries. Public information shows that CSPC Pharmaceutical Group Limited is the first super-large pharmaceutical enterprise in China formed through strong alliances, and it is one of the leading companies in China's pharmaceutical industry. Internationalization has been another core strategy actively promoted by CSPC in recent years.
 

CSPC Pharmaceutical Group Limited’s 2018 annual report revealed that, in the area of innovative drugs, the company actively leveraged external resources to expand its market share by accelerating acquisitions and collaborations. In 2018, it acquired a 39.56% equity stake in Wuhan YZ Biopharmaceutical Co., Ltd. and a 100% equity stake in Yongshun Technology Development Co., Ltd., and entered into collaborations with Shanghai Junshi Biosciences, Shanghai Institute of Materia Medica, and Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd. for new drug development and clinical studies.
 

Tasly Pharmaceutical: 91st
 

Tasly Pharmaceutical ranked 91st with a total revenue of RMB 14,301.54 million from strategic emerging industries.
 

According to the annual report publicly disclosed by Tasly Pharmaceutical, the company achieved an operating revenue of RMB 17.99 billion in 2018, representing a year-on-year increase of 11.78%; the net profit attributable to shareholders of the parent company amounted to RMB 1.55 billion, reflecting a year-on-year growth of 12.25%.
 

During the reporting period, the Company’s R&D investment in 2018 amounted to RMB 1.202 billion, accounting for 16.87% of its pharmaceutical industry revenue. Focusing on the three major therapeutic areas of cardiovascular and cerebrovascular diseases, digestive and metabolic disorders, and oncology, the Company has continued to strategically allocate resources across the research and development of modern traditional Chinese medicines, biological products, and chemical drugs, thereby creating space for future growth.
 

In addition, Tasly Pharmaceutical has partnered with the French company Pharnext, positioning it to potentially become the first Chinese pharmaceutical enterprise to possess AI-driven drug screening capabilities, thereby accelerating the advancement of its disease gene network R&D strategy.
 

　　Mindray: 96th
 

Mindray ranked 96th with a total strategic emerging industry revenue of RMB 13,753.35 million.
 

Mindray’s 2018 annual report showed that the company achieved a total operating revenue of RMB 13.753 billion in 2018, a year-on-year increase of 23.09%; net profit amounted to RMB 3.719 billion, a significant year-on-year increase of 43.65%.
 

Public information indicates that Mindray is primarily engaged in the research and development, manufacturing, marketing, and servicing of medical devices. As a global leading supplier of medical devices and solutions, its product portfolio spans three major sectors: Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging. It is reported that since its listing on the Shenzhen Stock Exchange, Mindray has prioritized technological innovation and closely aligned with clinical needs. Its products now reach nearly 110,000 medical institutions across China, covering over 99% of Grade A tertiary hospitals. By helping these institutions improve healthcare conditions, reduce costs, and deliver high-quality medical services, Mindray has also driven the standardized development of China’s medical device industry.
 

Kangmei Pharmaceutical Co.,Ltd: 98th
 

Kangmei Pharmaceutical Co., Ltd ranked 98th with a total revenue of RMB 13,342.47 million from strategic emerging industries. The 2018 annual report of Kangmei Pharmaceutical showed that the company achieved an operating revenue of RMB 19.356 billion in 2018, a year-on-year increase of 10.11%; the net profit attributable to shareholders of the listed company was RMB 1.135 billion, a year-on-year decrease of 47.20%.
 

It is reported that Kangmei Pharmaceutical Co., Ltd. has consistently aligned with the Belt and Road Initiative and the Healthy China strategy, actively supporting the national targeted poverty alleviation campaign and advancingTraditional Chinese Medicinal MaterialsIn its modernization drive, the company also prioritizes ecological civilization and the development of a low-carbon economy as key strategies to promote sustainable corporate growth, thereby advancing green and environmentally friendly development in the traditional Chinese medicine industry.